Dr. Lacouture On Preventing Dermatological Adverse Events in Melanoma

Video

In Partnership With:

Mario E. Lacouture, MD, a dermatologist with Memorial Sloan Kettering Cancer Center, explains how providers can manage adverse events that result from melanoma therapies.

Mario E. Lacouture, MD,

a dermatologist with Memorial Sloan Kettering Cancer Center, explains how providers can manage adverse events that result from melanoma therapies.

BRAF and MEK inhibitors have numerous common side effects that can sometimes cause patients to discontinue therapy. However, there are several ways that providers can work with patients to avoid these side effects, says Lacouture.

Using a topical cortical steroid and oral antibiotic proactively can reduce the severity of acneiform rash, often caused by MEK inhibitors. Hyperkeratosis of the hands and feet and dry skin, which are common side effects of BRAF inhibitors, can be prevented by advising the patient to use a moisturizer with exfoliate activity.

Patients on certain types of BRAF inhibitors also experience photosensitivity. This can result in severe sunburn with blisters after only 10 to 20 minutes of sun exposure. Patients on this therapy should be advised to take the necessary precautions to avoid sun exposure, says Lacouture.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD
Sundar Jagannath, MBBS
Nikhil Gopal, MD, assistant professor, urology, College of Medicine, Memphis Department of Urology, The University of Tennessee Health Science Center
Ashwin Kishtagari, MD
Somedeb Ball, MBBS
Lauren E. Nye, MD
Jonathan E. Rosenberg, MD